As the most potent CELMoD, mezigdomide results in the rapid degradation of Ikaros and Aiolos substrate proteins and induction of apoptosis in MM cells, together with strong stimulation of the immune system, and thus has a differentiated preclinical profile compared to the IMiD compounds. This evidence concerns the gene IKZF1 and Miyoshi myopathy.